Vipivotide tetraxetan
Catalog No.
A9982
A potent prostate-specific membrane antigen (PSMA) inhibitor
Featured Products
Vipivotide tetraxetan (PSMA-617) is a targeted drug for prostate cancer, with the ability to strongly inhibit prostate-specific membrane antigen (PSMA) with a Ki value of 0.37 nM. The Vipivotide tetraxetan is made up of three key components: the pharmacophoric Glutamate urea Lysine, the chelating agent DOTA (which binds radionuclides such as ^68Ga or ^177Lu), and the linker that connects the two parts. Among them, the Glutamate-urea-Lysine structure can selectively bind to the PSMA on the surface of prostate cancer cells, so as to achieve precise targeting. By binding radionuclides with DOTA chelating agent, Vipivotide tetraxetan can be used for diagnostic imaging or targeted radiation therapy for prostate cancer.
| Storage | Store at -20°C for 3 years. |
| M.Wt | 1042.15 |
| Cas No. | 1702967-37-0 |
| Formula | C49H71N9O16 |
| Solubility | Soluble in DMSO |
| Chemical Name | (((S)-1-carboxy-5-((S)-3-(naphthalen-2-yl)-2-((1r,4S)-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)-L-glutamic acid |
| SDF | Download SDF |
| Canonical SMILES | O=C(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)NC[C@@H]2CC[C@@H](C(N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)CC3=CC=C(C=CC=C4)C4=C3)=O)CC2 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
-
Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
